|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shroff EH, Eberlin LS, Dang VM, Gouw AM,
Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana
A, et al: MYC oncogene overexpression drives renal cell carcinoma
in a mouse model through glutamine metabolism. Proc Natl Acad Sci
USA. 112:6539–6544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Juengel E, Afschar M, Makarević J, Rutz J,
Tsaur I, Mani J, Nelson K, Haferkamp A and Blaheta RA: Amygdalin
blocks the in vitro adhesion and invasion of renal cell carcinoma
cells by an integrin-dependent mechanism. Int J Mol Med.
37:843–850. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He YH, Chen C and Shi Z: The biological
roles and clinical implications of microRNAs in clear cell renal
cell carcinoma. J Cell Physiol. 233:4458–4465. 2018. View Article : Google Scholar
|
|
6
|
Sullivan S: Paraneoplastic cough and renal
cell carcinoma. Can Respir J. 2016:59385362016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flanigan RC, Campbell SC, Clark JI and
Picken MM: Metastatic renal cell carcinoma. Curr Treat Options
Oncol. 4:385–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar
|
|
9
|
Thakur A and Jain SK: Kidney cancer:
Current progress in treatment. World J Oncol. 2:158–165.
2011.PubMed/NCBI
|
|
10
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Yuan Y, Liang P, Guo X, Ying Y,
Shu X-S, Gao M Jr and Cheng Y: OSR1 is a novel epigenetic silenced
tumor suppressor regulating invasion and proliferation in renal
cell carcinoma. Oncotarget. 8:30008–30018. 2017.PubMed/NCBI
|
|
12
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rini BI: New strategies in kidney cancer:
Therapeutic advances through understanding the molecular basis of
response and resistance. Clin Cancer Res. 16:1348–1354. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Z, Zhu R and Zheng J, Chen C, Huang
C, Ma J, Xu C, Zhai W and Zheng J: Cryptotanshinone inhibits
proliferation yet induces apoptosis by suppressing STAT3 signals in
renal cell carcinoma. Oncotarget. 8:50023–50033. 2017.PubMed/NCBI
|
|
15
|
Yamaguchi M and Yamamoto T: Purification
of calcium binding substance from soluble fraction of normal rat
liver. Chem Pharm Bull (Tokyo). 26:1915–1918. 1978. View Article : Google Scholar
|
|
16
|
Yamaguchi M and Sakurai T: Inhibitory
effect of calcium-binding protein regucalcin on
Ca2+-activated DNA fragmentation in rat liver nuclei.
FEBS Lett. 279:281–284. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shimokawa N and Yamaguchi M: Molecular
cloning and sequencing of the cDNA coding for a calcium-binding
protein regucalcin from rat liver. FEBS Lett. 327:251–255. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimokawa N, Matsuda Y and Yamaguchi M:
Genomic cloning and chromosomal assignment of rat regucalcin gene.
Mol Cell Biochem. 151:157–163. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thiselton DL, McDowall J, Brandau O,
Ramser J, d’Esposito F, Bhattacharya SS, Ross MT, Hardcastle AJ and
Meindl A: An integrated, functionally annotated gene map of the
DXS8026-ELK1 interval on human Xp11.3-Xp11.23: Potential hotspot
for neurogenetic disorders. Genomics. 79:560–572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamaguchi M and Isogai M: Tissue
concentration of calcium-binding protein regucalcin in rats by
enzyme-linked immunoadsorbent assay. Mol Cell Biochem. 122:65–68.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakagawa T and Yamaguchi M: Hormonal
regulation on regucalcin mRNA expression in cloned normal rat
kidney proximal tubular epithelial NRK52E cells. J Cell Biochem.
95:589–597. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamaguchi M: Role of regucalcin in
maintaining cell homeostasis and function (Review). Int J Mol Med.
15:371–389. 2005.PubMed/NCBI
|
|
23
|
Yamaguchi M: Regucalcin and cell
regulation: role as a suppressor in cell signaling. Mol Cell
Biochem. 353:101–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaguchi M: The potential role of
regucalcin in kidney cell regulation: Involvement in renal failure
(Review). Int J Mol Med. 36:1191–1199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi M: Role of regucalcin in cell
nuclear regulation: Involvement as a transcription factor. Cell
Tissue Res. 354:331–341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamaguchi M: Suppressive role of
regucalcin in liver cell proliferation: Involvement in
carcinogenesis. Cell Prolif. 46:243–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamaguchi M: The anti-apoptotic effect of
regucalcin is mediated through multisignaling pathways. Apoptosis.
18:1145–1153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamaguchi M: The Role of Regucalcin in
Cell Homeostasis and Disorder. Nova Science Publishers Inc.; New
York, NY: pp. 1–288. 2017
|
|
29
|
Yamaguchi M: Involvement of regucalcin as
a suppressor protein in human carcinogenesis: Insight into the gene
therapy. J Cancer Res Clin Oncol. 141:1333–1341. 2015. View Article : Google Scholar
|
|
30
|
Murata T and Yamaguchi M: Alternatively
spliced variants of the regucalcin gene in various human normal and
tumor tissues. Int J Mol Med. 34:1141–1146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yamaguchi M, Osuka S, Weitzmann MN,
El-Rayes BF, Shoji M and Murata T: Prolonged survival in pancreatic
cancer patients with increased regucalcin gene expression:
Overexpression of regucalcin suppresses the proliferation in human
pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol.
48:1955–1964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamaguchi M, Osuka S, Weitzmann MN, Shoji
M and Murata T: Increased regucalcin gene expression extends
survival in breast cancer patients: Overexpression of regucalcin
suppresses the proliferation and metastatic bone activity in
MDA-MB-231 human breast cancer cells in vitro. Int J Oncol.
49:812–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamaguchi M, Osuka S, Weitzmann MN,
El-Rayes BF, Shoji M and Murata T: Prolonged survival in
hepatocarcinoma patients with increased regucalcin gene expression:
HepG2 cell proliferation is suppressed by overexpression of
regucalcin in vitro. Int J Oncol. 49:1686–1694. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamaguchi M, Osuka S, Shoji M, Weitzmann
MN and Murata T: Survival of lung cancer patients is prolonged with
higher regucalcin gene expression: Suppressed proliferation of lung
adenocarcinoma A549 cells in vitro. Mol Cell Biochem. 430:37–46.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamaguchi M, Osuka S and Murata T:
Prolonged survival of colorectal cancer patients is associated with
higher regucalcin gene expression: Overexpressed regucalcin
suppresses growth of human colorectal carcinoma cells in vitro. Int
J Oncol. 53:1313–1322. 2018.PubMed/NCBI
|
|
36
|
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao
A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L,
Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Uhlen M, Oksvold P, Fagerberg L, Lundberg
E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S,
et al: Towards a knowledge-based Human Protein Atlas. Nat
Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar
|
|
39
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:e742502013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma X, Gu L, Li H, Gao Y, Li X, Shen D,
Gong H, Li S, Niu S, Zhang Y, et al: Hypoxia-induced overexpression
of stanniocalcin-1 is associated with the metastasis of early stage
clear cell renal cell carcinoma. J Transl Med. 13:562015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Misawa H, Inagaki S and Yamaguchi M:
Suppression of cell proliferation and deoxyribonucleic acid
synthesis in the cloned rat hepatoma H4-II-E cells overexpressing
regucalcin. J Cell Biochem. 84:143–149. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z,
Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: Simvastatin inhibits
renal cancer cell growth and metastasis via AKT/mTOR, ERK and
JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamaguchi M and Daimon Y: Overexpression
of regucalcin suppresses cell proliferation in cloned rat hepatoma
H4-II-E cells: Involvement of intracellular signaling factors and
cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Izumi T and Yamaguchi M: Overexpression of
regucalcin suppresses cell death in cloned rat hepatoma H4-II-E
cells induced by tumor necrosis factor-alpha or thapsigargin. J
Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Charollais RH, Buquet C and Mester J:
Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but
inhibits both the early and late G1 progression in chemically
transformed mouse fibroblasts BP–A31. J Cell Physiol. 145:46–52.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Meijer L, Borgne A, Mulner O, Chong JP,
Blow JJ, Inagaki N, Inagaki M, Delcros JG and Moulinoux JP:
Biochemical and cellular effects of roscovitine, a potent and
selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and
cdk5. Eur J Biochem. 243:527–536. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Singh SV, Herman-Antosiewicz A, Singh AV,
Lew KL, Srivastava SK, Kamath R, Brown KD, Zhang L and Baskaran R:
Sulforaphane-induced G2/M phase cell cycle arrest involves
checkpoint kinase 2-mediated phosphorylation of cell division cycle
25C. J Biol Chem. 279:25813–25822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nakagawa T, Sawada N and Yamaguchi M:
Overexpression of regucalcin suppresses cell proliferation of
cloned normal rat kidney proximal tubular epithelial NRK52E cells.
Int J Mol Med. 16:637–643. 2005.PubMed/NCBI
|
|
50
|
Serrano-Nascimento C, da Silva Teixeira S,
Nicola JP, Nachbar RT, Masini-Repiso AM and Nunes MT: The acute
inhibitory effect of iodide excess on sodium/iodide symporter
expression and activity involves the PI3K/Akt signaling pathway.
Endocrinology. 155:1145–1156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pelech SL, Charest DL, Mordret GP, Siow
YL, Palaty C, Campbell D, Charlton L, Samiei M and Sanghera JS:
Networking with mitogen-activated protein kinases. Mol Cell
Biochem. 127–128. 157–169. 1993.
|
|
52
|
Tamaoki T, Nomoto H, Takahashi I, Kato Y,
Morimoto M and Tomita F: Staurosporine, a potent inhibitor of
phospholipid/Ca++ dependent protein kinase. Biochem
Biophys Res Commun. 135:397–402. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Palangat M, Grass JA, Langelier MF,
Coulombe B and Landick R: The RPB2 flap loop of human RNA
polymerase II is dispensable for transcription initiation and
elongation. Mol Cell Biol. 31:3312–3325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tang SC and Chen YC: Novel therapeutic
targets for pancreatic cancer. World J Gastroenterol.
20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tsurusaki Y and Yamaguchi M: Role of
regucalcin in liver nuclear function: Binding of regucalcin to
nuclear protein or DNA and modulation of tumor-related gene
expression. Int J Mol Med. 14:277–281. 2004.PubMed/NCBI
|
|
56
|
Tsurusaki Y and Yamaguchi M:
Overexpression of regucalcin modulates tumor-related gene
expression in cloned rat hepatoma H4-II-E cells. J Cell Biochem.
90:619–626. 2003. View Article : Google Scholar : PubMed/NCBI
|
